|
業務類別
|
Biotechnology |
|
業務概覽
|
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909. |
| 公司地址
| 99 Coolidge Avenue, Suite 500, Watertown, MA, USA, 02472 |
| 電話號碼
| +1 617 586-3100 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.foghorntx.com |
| 員工數量
| 106 |
| Mr. Ryan D. Maynard |
Chief Financial Officer and Principal Accounting Officer |
-- |
23/02/2026 |
| Mr. Michael J. LaCascia |
Chief Legal Officer |
-- |
30/04/2026 |
| Mr. Adrian Gottschalk |
President, Chief Executive Officer and Director |
美元 638.00K |
30/04/2026 |
| Dr. Steven F. Bellon, PhD |
Chief Scientific Officer |
美元 505.00K |
30/04/2026 |
| Mr. Carlos Costa |
Chief People Officer |
-- |
30/04/2026 |
| Dr. Alfonso Quintas-Cardama, M.D. |
Chief Medical Officer |
美元 494.00K |
30/04/2026 |
| Dr. Anna Rivkin, PhD |
Chief Business Officer |
-- |
30/04/2026 |
| Mr. Jeff Sacher |
Treasurer |
-- |
23/02/2026 |
|
|
| Ms. B. Lynne Parshall, Esq.,J.D. |
Independent Director |
30/04/2026 |
| Mr. Ian F. Smith |
Independent Director |
30/04/2026 |
| Dr. Douglas G. Cole, M.D. |
Chairman of the Board |
30/04/2026 |
| Dr. Thomas J. Lynch, Jr,M.D. |
Independent Director |
30/04/2026 |
| Dr. Scott Biller, PhD |
Independent Director |
30/04/2026 |
| Dr. Balkrishan Gill, PhD |
Independent Director |
30/04/2026 |
| Dr. Michael Mendelsohn, M.D. |
Independent Director |
30/04/2026 |
| Mr. Adrian Gottschalk |
President, Chief Executive Officer and Director |
30/04/2026 |
| Mr. Stuart M. Duty |
Independent Director |
30/04/2026 |
| Dr. Neil Gallagher, M.D.,PhD |
Independent Director |
30/04/2026 |
|
|
|
|
